This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Qiagen (QGEN) was downgraded to a Hold Rating at J.P. Morgan
Qiagen received a Hold rating and price target from J.P. Morgan analyst Casey Woodring today.
According to TipRanks, Woodring is a 5-star analyst with an average return of 12.7% and a 67.41% success rate. Woodring covers the Healthcare sector, focusing on stocks such as Illumina, Qiagen, and Guardant Health.
Currently, the analyst consensus on Qiagen is a Moderate Buy with an average price target of $47.21.
Based on Qiagen’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $535.04 million and a net profit of $103.4 million. In comparison, last year the company earned a revenue of $533.54 million and had a net profit of $96.25 million
Read More on QGEN:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
